{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T05:46:33Z","timestamp":1751003193227},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Atrial fibrillation is the most important risk factor for left atrial appendage (LAA) thrombi, a potentially life\u2010threatening condition. Thrombus resolution may prevent embolic events and allow rhythm\u2010control strategies, which have been shown to reduce cardiovascular complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Hypothesis<\/jats:title><jats:p>There is no significant difference between phenprocoumon and non\u2010Vitamin K\u2010dependent oral anticoagulants (NOACs) in the resolution of LAA\u2010thrombi in a real\u2010world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Consecutive patients with LAA\u2010thrombi from June 2013 to June 2017 were included in an observational single\u2010center analysis. The primary endpoint was defined as the resolution of the thrombus. The observational period was 1 year. Resolutions rates in patients on phenprocoumon or NOACs were compared and the time to resolution was analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 114 patients with LAA\u2010thrombi. There was no significant difference in the efficacy of resolution between phenprocoumon and NOACs (<jats:italic>p<\/jats:italic>\u2009=\u2009.499) at the time of first control which took place after a mean of 58\u2009\u00b1\u200942.2 (median 48) days. At first control most thrombi were dissolved (74.6%). The analysis after set\u2010time intervals revealed a resolution rate of 2\/3 of LAA\u2010thrombi after 8\u201310 weeks in the phenprocoumon and NOAC groups. After 12 weeks a higher number of thrombi had resolved in the presence of NOAC (89.3%) whereas in the presence of phenprocoumon 68.3% had resolved (<jats:italic>p<\/jats:italic>\u2009=\u2009.046).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this large observational study NOACs were found to be potent drugs for the resolution of LAA\u2010thrombi. In addition, the resolution of LAA\u2010thrombi was found to be faster in the presence of NOAC as compared to phenprocoumon.<\/jats:p><\/jats:sec>","DOI":"10.1002\/clc.23823","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:08:28Z","timestamp":1649074108000},"page":"650-656","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Resolution of left atrial appendage thrombi: No difference between phenprocoumon and non\u2010vitamin K\u2010dependent oral antagonists"],"prefix":"10.1002","volume":"45","author":[{"given":"Katharina","family":"Biller","sequence":"first","affiliation":[{"name":"Department\u00a0of Cardiology I\u2014Coronary and Peripheral Vascular Disease, Heart Failure University Hospital M\u00fcnster Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Biller","sequence":"additional","affiliation":[{"name":"Department of Cardiology II\u2014Electrophysiology University Hospital M\u00fcnster Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannes","family":"Findeisen","sequence":"additional","affiliation":[{"name":"Department\u00a0of Cardiology I\u2014Coronary and Peripheral Vascular Disease, Heart Failure University Hospital M\u00fcnster Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Eckardt","sequence":"additional","affiliation":[{"name":"Department of Cardiology II\u2014Electrophysiology University Hospital M\u00fcnster Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horst","family":"Wedekind","sequence":"additional","affiliation":[{"name":"Department of Cardiology St. Franziskus\u2010Hospital M\u00fcnster Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70089-5"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.304488"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.24.1.35"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.27.10.1760"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.010942"},{"key":"e_1_2_9_7_1","article-title":"Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non\u2010valvular atrial fibrillation and no history of stroke or transient ischemic attacks","author":"Aguilar MI","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019422"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","unstructured":"HindricksG PotparaT DagresN et al ESC Scientific Document Group.ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio\u2010Thoracic Surgery (EACTS).Eur Heart J.2020.\u00a0doi:10.1093\/eurheartj\/ehaa612","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2016.05.007"},{"key":"e_1_2_9_11_1","first-page":"776","article-title":"Oral anticoagulation","volume":"115","author":"Altiok E","year":"2018","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_2_9_12_1","unstructured":"\u00c4rzteschaft Add. Leitfaden \u201corale Antikoagulation bei nicht valvul\u00e4rem Vorhofflimmern\u201d Empfehlungen zum Einsatz der direkten oralen Antokoagulanzien Dabigatran (Pradaxa) Apixaban (Eliquis) Edoxaban (Lixiana) und Rivaroxaban (Xarelto). 2018.\u00a0\u00a0https:\/\/www.akdae.de\/Arzneimitteltherapie\/LF\/PDF\/OAKVHF.pdf"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jev014"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2018.09.026"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2000.106648"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.2.160"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00775-z"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.23823","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/clc.23823","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.23823","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T19:29:10Z","timestamp":1692818950000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.23823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1002\/clc.23823"],"URL":"https:\/\/doi.org\/10.1002\/clc.23823","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"assertion":[{"value":"2021-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}